Differential Expression of TRAIL and its Receptors in Benign and Malignant Prostate Tissues
- 31 January 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 177 (1) , 359-364
- https://doi.org/10.1016/j.juro.2006.08.087
Abstract
Conclusions Due to high TRAIL-R4 expression in all patient groups complementary gene therapy modalities might be needed to bypass potential TRAIL-R4 induced resistance.Keywords
This publication has 16 references indexed in Scilit:
- Adenovirus-mediated IKKβKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosisCancer Gene Therapy, 2005
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Enhancement of Apo2L/TRAIL (tumor necrosis factor–related apoptosis-inducing ligand)–induced apoptosis in non–small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory proteinThe Journal of Thoracic and Cardiovascular Surgery, 2002
- Cellular stress response and apoptosis in cancer therapyBlood, 2001
- Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced ApoptosisPublished by Elsevier ,2001
- The potential of TRAIL for cancer chemotherapyApoptosis, 2001
- New Prospectives of Prostate Cancer Gene Therapy: Molecular Targets and Animal ModelsCritical Reviews™ in Eukaryotic Gene Expression, 2001
- The TRAIL to selective tumor deathNature Medicine, 1999
- TRAIL: a molecule with multiple receptors and control mechanismsCurrent Opinion in Immunology, 1998
- Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy ReceptorsScience, 1997